Manipal Health Enterprises Ltd (MANIPALHOS) Q1 FY27 Earnings Call: Guides Rs.4,000 Cr Capex, 24.2% Network Margin

Manipal Health Enterprises Ltd held its Q1 FY27 earnings call on August 20, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Volume-Led Revenue Growth with 24.2% Network Margin

• Revenue Rs.3,091 crore in Q1 FY 2026-2027 — up 38% YoY, driven by inpatient volumes (+39% YoY) and outpatient volumes (+26% YoY), with volume-led growth across the network.
• Network EBITDA Rs.749 crore — up 26% YoY (+30% excluding a one-off gain), with network margin at 24.2%; ex-Sahyadri margin at 25%.
• Network occupancy of 65% — improved 290bps YoY, with industry-leading ALOS of 2.7 days; ARPOB ex-Sahyadri at Rs.77,200/day (+9% YoY).
• Digital revenue reached Rs.710 crore — 23% of total revenue; e-pharmacy processed 15,000+ orders across 23 hospitals; telehealth 17,000+ consultations; AI chatbot handled 9,600+ interactions.
• Centres of Excellence drove 65% of revenue — cardiology, oncology, neurology, gastroenterology, orthopedics, and renal sciences; IP revenue in these specialties grew 45% YoY.
• Ex-Sahyadri core margin declined 1.5% YoY to 25% — but excluding a Rs.15 crore one-off Medica reversal in Q1 FY 2025-2026, the decline was only 0.9%; greenfield doctor costs dragged margins by >0.5% in Q1 FY 2026-2027.

17.5% Margin with 16-18 Month Playbook to Close the Gap

• Sahyadri contributed Rs.332 crore revenue in Q1 FY 2026-2027 — up 13% YoY, with EBITDA of Rs.58 crore (+19%) and margin of 17.5%; ARPOB improved 15% to Rs.45,000/day, occupancy at 63%, ALOS reduced 8% to 2.8 days.
• Integration playbook spans 16-18 months — priorities include clinician interoperability across 58 doctors in Pune, brand re-christening to Manipal in 14-16 months, digital channel penetration of 22-23% of revenue, and infrastructure upgrades to Manipal standards.
• Onco-case complexity is the key margin gap — management is targeting an upward shift in case complexity at Sahyadri to narrow the gap to the network average.
• Network onco mix grew from 10.8% (FY 2025-2026) to 12.2% (Q1 FY 2026-2027) — oncology growing at ~45% overall, among the fastest segments; onco-case complexity, not mix contribution, differentiates Sahyadri margins.
• Expansion underway at multiple Sahyadri units — Deccan Gymkhana tower addition, Hadapsar bed expansion, greenfield in Wakad (North Pune), and Nashik added 100+ oncology beds with LINAC and PET-CT.
• Government scheme transition in the East under discussion — management cited ongoing discussions with authorities and "expects it to be resolved shortly"; government business remained flat while cash and TPA revenue grew 22% YoY in the East.

Rs.4,000 Cr Capex Over 3-4 Years; 1,000+ Beds in Active Pipeline

• CAPEX guidance of ~Rs.4,000 crore over FY 2026-2027 through ~FY 2029-2030 — to add 3,000 beds; for FY 2026-2027, expected CAPEX of ~Rs.2,000 crore (Rs.900 crore already spent in Q1).
• ~300-bed Electronic City facility commissioning in Q2 FY 2026-2027 — takes Bangalore's licensed capacity to ~3,000 beds across 13 facilities.
• Raipur hospital commissioning in Q4 FY 2026-2027 — a 100-bed women & children facility in Whitefield, Bangalore, is scheduled between Raipur and the Mumbai greenfield (FY 2029).
• Kinder Hospital acquisition adds ~100 beds in Whitefield — a sub-100 bed add-on in a high-growth micro-market where Manipal already operates two hospitals; facility will close for 6-7 months for renovation and conversion to multi-specialty; transfer expected within 60 days.
• For FY 2027-2028, Aliyah Nagar expected to add ~80 beds — as part of the ongoing bed expansion program.
• No additional significant greenfield until Mumbai (FY 2029) — management confirmed Raipur and Whitefield as the next milestones; minimum greenfield size remains 250-300 beds.

Deleveraged Balance Sheet at 0.9x Debt/EBITDA Supports Inorganic Ambitions

• Net debt/EBITDA expected at 0.9x after Q2 FY 2026-2027 debt repayment — management comfortable operating at 1.5-2.0x leverage, may go higher for compelling opportunities.
• Core revenue growth of 23% ex-Sahyadri in Q1 FY 2026-2027 — volume-led and considered secular by management, with no one-off seasonality; tailwinds from greenfield ramp and Pune capacity additions for the remaining three quarters of FY 2026-2027.
• Greenfields ramping ahead of plan — Kanakapura achieved EBITDA breakeven in month 5, Yelahanka in month 2; both posted 13% EBITDA margin in Q1 FY 2026-2027.
• Management has no plans for medical colleges in the listed entity — Dilip Jose confirmed the company will remain focused on tertiary and quaternary care.
• Deleveraged balance sheet provides inorganic capacity — management cited new geographies including Kerala, NCR, and Hyderabad as potential targets for expansion.
• International patient revenue grew 65% YoY in Q1 FY 2026-2027 — accounting for 3% of revenue; government payers constitute 14% of the payer mix.

Oncology and International Segments Accelerate; ALOS at Industry-Leading 2.7 Days

• Oncology mix grew to 12.2% of network revenue in Q1 FY 2026-2027 — up from 10.8% in FY 2025-2026, with oncology growing at ~45% overall; Delhi NCR program already strong, additional oncology capacity commissioned in three Bangalore greenfields over the past 12 months.
• Industry-leading ALOS of 2.7 days — improved from 4.2-4.3 days (historical level), driven by reducing administrative inefficiencies and planned discharges; lower than peer range of 3.5-4 days.
• ARPOB ex-Sahyadri at Rs.77,200/day (+9% YoY) — Sahyadri ARPOB improved 15% to Rs.45,000/day, reflecting case-mix improvement and pricing discipline.
• AMRI grew 17% YoY and Medica grew 15% YoY in Q1 FY 2026-2027 — East region cash and TPA revenue up 22% YoY; management stated margins for acquired entities are on the planned trajectory.
• Portfolio hospitals with margins exceeding 30% — management cited several facilities operating above 30% margin, aiming to guide the entire network towards further improvement.
• The ex-Sahyadri network at 25% margin — with Sahyadri at ~17-17.5%, management plans to push Sahyadri closer to portfolio margin over time.